Cargando…

The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats

BACKGROUND: Maraviroc is an antiretroviral agent and C-C chemokine coreceptor 5 (CCR5) antagonist that is currently used to treat human immunodeficiency virus. CCR5/μ-opioid receptor heterodimerization suggests that maraviroc could be a treatment for oxycodone abuse. We treated rats with maraviroc t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iriah, Sade C., Borges, Catarina, Shalev, Uri, Cai, Xuezhu, Madularu, Dan, Kulkarni, Praveen P., Ferris, Craig F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Joule Inc. 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526136/ https://www.ncbi.nlm.nih.gov/pubmed/34625487 http://dx.doi.org/10.1503/jpn.200191

Ejemplares similares

BOLD Imaging in Awake Wild-Type and Mu-Opioid Receptor Knock-Out Mice Reveals On-Target Activation Maps in Response to Oxycodone
por: Moore, Kelsey, et al.
Publicado: (2016)

Neuroradiological Changes Following Single or Repetitive Mild TBI
por: Kulkarni, Praveen, et al.
Publicado: (2019)

Life without a brain: Neuroradiological and behavioral evidence of neuroplasticity necessary to sustain brain function in the face of severe hydrocephalus
por: Ferris, C. F., et al.
Publicado: (2019)

Using multimodal MRI to investigate alterations in brain structure and function in the BBZDR/Wor rat model of type 2 diabetes
por: Lawson, Christopher M., et al.
Publicado: (2020)

Data on MRI brain lesion segmentation using K-means and Gaussian Mixture Model-Expectation Maximization
por: Qiao, Ju, et al.
Publicado: (2019)

RNaseT2 knockout rats exhibit hippocampal neuropathology and deficits in memory
por: Sinkevicius, Kerstin W., et al.
Publicado: (2018)

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
por: De Luca, Andrea, et al.
Publicado: (2019)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
por: López-Huertas, María Rosa, et al.
Publicado: (2020)

Imaging the effect of the circadian light–dark cycle on the glymphatic system in awake rats
por: Cai, Xuezhu, et al.
Publicado: (2020)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Alterations in brain neurocircuitry following treatment with the chemotherapeutic agent paclitaxel in rats
por: Ferris, Craig F., et al.
Publicado: (2019)

Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc
por: Vincent, Kathleen Listiak, et al.
Publicado: (2018)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment
por: Shikuma, Cecilia M., et al.
Publicado: (2023)

Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV
por: Matt, Stephanie M., et al.
Publicado: (2021)

Pattern of buprenorphine abuse among opioid abusers in Nepal
por: Aich, Tapas Kumar, et al.
Publicado: (2010)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
por: Ostrowski, Mario, et al.
Publicado: (2015)

Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc
por: Borm, Katharina, et al.
Publicado: (2016)

Designing Opioids That Deter Abuse
por: Raffa, Robert B., et al.
Publicado: (2012)

Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial
por: Belaunzarán-Zamudio, Pablo F., et al.
Publicado: (2017)

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
por: Coplan, PM, et al.
Publicado: (2016)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Dose‐dependent effects of esketamine on brain activity in awake mice: A BOLD phMRI study
por: Kawazoe, Kyrsten, et al.
Publicado: (2022)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

How to prevent opioid abuse and addiction
por: Hwang, Sung Mi
Publicado: (2023)

Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse
por: Cepeda, M. Soledad, et al.
Publicado: (2014)

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
por: Lafeuillade, Alain, et al.
Publicado: (2014)

Risk of behaviour suggestive of opioid abuse: a protocol for a systematic review of validated assessment tools
por: Galindo, Sheila Raposo, et al.
Publicado: (2018)

Functional magnetic resonance imaging in awake transgenic fragile X rats: evidence of dysregulation in reward processing in the mesolimbic/habenular neural circuit
por: Kenkel, W M, et al.
Publicado: (2016)

The Serotonin Receptor 6 Antagonist Idalopirdine and Acetylcholinesterase Inhibitor Donepezil Have Synergistic Effects on Brain Activity—A Functional MRI Study in the Awake Rat
por: Ferris, Craig F., et al.
Publicado: (2017)

Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc
por: Lewis, ME, et al.
Publicado: (2021)

Effect of opioid dependence or abuse on opioid utilization after shoulder arthroplasty
por: Berglund, Derek D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ih0gi92fkour5is4ulqsngmbbj